Roche Pegasys/Copegus combo approval
This article was originally published in Pharmaceutical Approvals Monthly
FDA clears Roche's Pegasys (peginterferon alfa-2a) Dec. 3 for combination use with Copegus (ribavirin) for treatment of adults with chronic hepatitis C and compensated liver disease who have not previously received interferon alfa. Dosing is based on viral genotype; the recommended dose is 180 mcg Pegasys plus 1,000-1,200 mg Copegus for 48 weeks for patients with HCV genotype 1 or 4, and 180 mcg Pegasys plus 800 mg Copegus for 24 weeks for genotype 2 or 3 patients. Labeling reports a 53% sustained virological response for Pegasys/Copegus compared to 44% for Schering-Plough's Rebetron (interferon alfa-2b/ribavirin) (Pharmaceutical Approvals Monthly, June 2002, p. 3). Pegasys monotherapy was approved Oct. 16. Roche says the combination therapy will launch in early 2003 when Copegus will be available in pharmacies; Copegus and Pegasys will be sold separatel
You may also be interested in...
DJO Global will buy Trilliant Surgical to further its ongoing expansion into the US foot and ankle market.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.